ArticleNature communications2018
HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 72 citations in OpenAlex.
- CARDIOKIN1: Computational Assessment of Myocardial Metabolic Capability in Healthy Controls and Patients With Valve Diseases.Circulation · 2021Trial
- Granulocyte differentiation arrest in HAX1-deficient cells, demonstrated in a new in vitro model of a certain phenotypic aspects of Kostmann disease, is caused by ineffective lipid droplet autophagy and fatty acids uptake.Cell death & disease · 2026Article
- Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety.Nature reviews. Drug discovery · 2026Review
- Modeling the dynamics of hepatic metabolism: the predominance of 12-hour rhythmicity in metabolic adaptation.Cellular and molecular life sciences : CMLS · 2026Article
- Quantitative systems toxicology approach that integrates PBPK and core hepatic metabolism: a case study with valproic acid.Frontiers in pharmacology · 2026Article
- Computational modelling of myocardial metabolism in patients with advanced heart failure.European journal of heart failure · 2025Article
- Patient-specific effects of metformin on the hepatic metabolism in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD).Journal of molecular medicine (Berlin, Germany) · 2025Article
- Comparative phenotyping of C57BL/6J substrains reveals distinctive patterns of cardiac aging.GeroScience · 2025Article
- Assessing customized multivalent chemokine-binding peptide treatment in a murine model of coxsackievirus B3 myocarditis.Basic research in cardiology · 2025Article
- Deciphering the cell type-specific and zonal distribution of drug-metabolizing enzymes, transporters, and transcription factors in livers of mice using single-cell transcriptomics.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Beyond hemoglobin: Critical role of 2,3-bisphosphoglycerate mutase in kidney function and injury.Acta physiologica (Oxford, England) · 2025Article
- Article
- Article
- Kinetic Modeling of Hepatic Metabolism and Simulation of Treatment Effects.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC.Neoplasia (New York, N.Y.) · 2023Article
- Fluorescence Imaging of Inflammation with Optical Probes.Chemical & biomedical imaging · 2023Review
- Multi-Modality, Multi-Dimensional Characterization of Pediatric Non-Alcoholic Fatty Liver Disease.Metabolites · 2023Article
- Digital twin demonstrates significance of biomechanical growth control in liver regeneration after partial hepatectomy.iScience · 2023Article
- Alterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemic increase of non-alcoholic fatty liver diseases (NAFLD) requires a deeper understanding of the regulatory circuits controlling the response of liver metabolism to nutritional challenges, medical drugs, and genetic enzyme variants. As in vivo studies of human liver metabolism are encumbered with serious ethical and technical issues, we developed a comprehensive biochemistry-based kinetic model of the central liver metabolism including the regulation of enzyme activities by their reactants, allosteric effectors, and hormone-dependent phosphorylation. The utility of the model for basic research and applications in medicine and pharmacology is illustrated by simulating diurnal variations of the metabolic state of the liver at various perturbations caused by nutritional challenges (alcohol), drugs (valproate), and inherited enzyme disorders (galactosemia). Using proteomics data to scale maximal enzyme activities, the model is used to highlight differences in the metabolic functions of normal hepatocytes and malignant liver cells (adenoma and hepatocellular carcinoma).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.